Articles About Tele |
Stop Parking Domain Names Develop Your Domain Names |
|||||||
Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
MELBOURNE, Australia (Business Wire EON) July 21, 2008 -- About 4 million people worldwide suffer from Inflammatory Bowel Disease, split roughly evenly between the two manifestations of the disease: Crohn's disease (CD) and ulcerative colitis (UC). IBD is a relapsing / remitting chronic disease with gastrointestinal symptoms such as diarrhoea, rectal bleeding and abdominal pain.
The study is led by a leading Israeli Gastroenterologist, Professor Zamir Halpern, Deputy Director of Tel Aviv Sourasky Medical Center and Chief of the Center's Gastroenterology Institute, and by Professor Nachum Vaisman, Head of the Unit of Clinical Nutrition.
The first patients have already been recruited and have entered the trial which is expected be completed during 2009. The trial is designed as an open study being run to confirm and expand upon human clinical data obtained from a pilot study at St Vincent's Hospital in Melbourne, which ended recently. Anadis intends to launch its colostrum-derived product as a medical food or nutritional immediately following the Tel Aviv trial. Anadis will meet all regulatory requirements during the conduct of the trial itself.
In addition to the initiation of this IBD study, Anadis recently announced being awarded a VISTECH grant for another study, also to be conducted at Tel Aviv Souraski Medical Center, towards the development and commercialization of a product to address cancer-related mucositis. See "Anadis Awarded VISTECH grant for Clinical Trial of Polyclonal Antibodies for the Treatment of Cancer Related Mucositis" - Tuesday 1 July 2008."
Tel Aviv Sourasky Medical Center (TASMC) is one of the largest hospitals in Israel with 1100 beds and is responsible for providing specialty care to the Tel Aviv metropolitan area. It is a teaching and research center affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dr Oren Fuerst, VP Business development of Anadis stated, "This is another illustration of the successful collaboration between Anadis and the researchers at TASMC. The leveraging of Australian manufacturing and core research, with research and clinical studies in Israel will allow us to bring products to market faster and at lower costs than otherwise. Our current plans calls for commercialization of both the IBD and the mucositis products within less than 2 years, addressing two major gastrointestinal diseases using our core platform."
Other Article Sites findabook.com moneycd.info a-mortgage.info
about-lemon-laws.info aboutstudentloans.info |
MORE ARTICLES: Data-Tel Info Solutions Broadens International Ties by Expanding Operations to Dominican Republic Data-Tel Info Solutions hires Mirla Lara as the new Regional Sales and Operations Director for the Dominican Republic.
Mysterious Tel Aviv Lifestyle 2004
Data-Tel Info Solutions Offers Transition Discount For Growing Hosted Clients
National Seminars Group Padgett Thompson Seminars Summer 2007 Training Seminars Added To FindaSeminar.com
Dr. Rick Wren and Zonsite Seminars Have Agreed to Dissolve Seminar 21 and Club 21
.tel Sunrise Period Opens with EuroDNS Today
DomainPeople Lets Trademark Owners Register Their .Tel Domain Name Early
Speed Money Seminar: New Internet Marketing Seminar To Be Held In Vancouver, BC Canada
Worldwide Phone Services Launched for Fixed Phones, Mobile Phones, and VoIP
Skillpath Seminars Spring/Summer Training Seminar Schedule Added To FindaSeminar.com
Pre-Register Your .TEL with EuroDNS Now
Compucall Web Marketing sponsors the Tel Aviv Entrepreneur Meetup Starring Jeff Pulver
TouchStar Acquires Direct Competitor Data-Tel
Netfirms Announces Availability of Innovative .TEL Domain Names
Data-Tel Info Solutions Announces New Hosted Agent Program
|
|||||||
| Develop Your Domain Names | Site Map | Home | ||||||||